Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort

on behalf of the PROSPR consortium

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Little is known about the effect of evolving risk-based cervical cancer screening and management guidelines on United States (US) clinical practice and patient outcomes. We describe the National Cancer Institute's Population-based Research Optimizing Screening through Personalized Regimens (PROSPR I) consortium, methods and baseline findings from its cervical sites: Kaiser Permanente Washington, Kaiser Permanente Northern California, Kaiser Permanente Southern California, Parkland Health & Hospital System/University of Texas Southwestern (Parkland-UTSW) and New Mexico HPV Pap Registry housed by University of New Mexico (UNM-NMHPVPR). Across these diverse healthcare settings, we collected data on human papillomavirus (HPV) vaccinations, screening tests/results, diagnostic and treatment procedures/results and cancer diagnoses on nearly 4.7 million women aged 18–89 years from 2010 to 2014. We calculated baseline (2012 for UNM-NMHPVPR; 2010 for other sites) frequencies for sociodemographics, cervical cancer risk factors and key screening process measures for each site's cohort. Healthcare delivery settings, cervical cancer screening strategy, race/ethnicity and insurance status varied among sites. The proportion of women receiving a Pap test during the baseline year was similar across sites (26.1–36.1%). Most high-risk HPV tests were performed either reflexively or as cotests, and utilization pattern varied by site. Prevalence of colposcopy or biopsy was higher at Parkland-UTSW (3.6%) than other sites (1.3–1.4%). Incident cervical cancer was rare. HPV vaccination among age-eligible women not already immunized was modest across sites (0.1–7.2%). Cervical PROSPR I makes available high-quality, multilevel, longitudinal screening process data from a large and diverse cohort of women to evaluate and improve the effectiveness of US cervical cancer screening delivery.

Original languageEnglish (US)
Pages (from-to)1460-1473
Number of pages14
JournalInternational Journal of Cancer
Issue number6
StatePublished - Mar 15 2019


  • Pap test
  • cancer screening
  • cervical cancer
  • human papillomavirus

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort'. Together they form a unique fingerprint.

Cite this